141 related articles for article (PubMed ID: 37759078)
1. CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor.
Duan L; Tadi MJ; Maki CG
Sci Rep; 2023 Sep; 13(1):16271. PubMed ID: 37759078
[TBL] [Abstract][Full Text] [Related]
2. RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC.
Duan L; Perez RE; Calhoun S; Maki CG
Sci Rep; 2022 Jan; 12(1):1049. PubMed ID: 35058503
[TBL] [Abstract][Full Text] [Related]
3. RB, p130 and p107 differentially repress G1/S and G2/M genes after p53 activation.
Schade AE; Fischer M; DeCaprio JA
Nucleic Acids Res; 2019 Dec; 47(21):11197-11208. PubMed ID: 31667499
[TBL] [Abstract][Full Text] [Related]
4. DREAM and RB cooperate to induce gene repression and cell-cycle arrest in response to p53 activation.
Uxa S; Bernhart SH; Mages CFS; Fischer M; Kohler R; Hoffmann S; Stadler PF; Engeland K; Müller GA
Nucleic Acids Res; 2019 Sep; 47(17):9087-9103. PubMed ID: 31400114
[TBL] [Abstract][Full Text] [Related]
5. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
Modi S; Kubo A; Oie H; Coxon AB; Rehmatulla A; Kaye FJ
Oncogene; 2000 Sep; 19(40):4632-9. PubMed ID: 11030152
[TBL] [Abstract][Full Text] [Related]
6. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
Fischer M; Quaas M; Nickel A; Engeland K
Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle regulation: p53-p21-RB signaling.
Engeland K
Cell Death Differ; 2022 May; 29(5):946-960. PubMed ID: 35361964
[TBL] [Abstract][Full Text] [Related]
8. The transcription factor p53: not a repressor, solely an activator.
Fischer M; Steiner L; Engeland K
Cell Cycle; 2014; 13(19):3037-58. PubMed ID: 25486564
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional repression of Aurora-A gene by wild-type p53 through directly binding to its promoter with histone deacetylase 1 and mSin3a.
Yang TY; Teng CJ; Lin TC; Chen KC; Hsu SL; Wu CC
Int J Cancer; 2018 Jan; 142(1):92-108. PubMed ID: 28884479
[TBL] [Abstract][Full Text] [Related]
10. p53 can repress transcription of cell cycle genes through a p21(WAF1/CIP1)-dependent switch from MMB to DREAM protein complex binding at CHR promoter elements.
Quaas M; Müller GA; Engeland K
Cell Cycle; 2012 Dec; 11(24):4661-72. PubMed ID: 23187802
[TBL] [Abstract][Full Text] [Related]
11. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
[TBL] [Abstract][Full Text] [Related]
12. Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence.
Litovchick L; Sadasivam S; Florens L; Zhu X; Swanson SK; Velmurugan S; Chen R; Washburn MP; Liu XS; DeCaprio JA
Mol Cell; 2007 May; 26(4):539-51. PubMed ID: 17531812
[TBL] [Abstract][Full Text] [Related]
13. Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.
Chung J; Karkhanis V; Tae S; Yan F; Smith P; Ayers LW; Agostinelli C; Pileri S; Denis GV; Baiocchi RA; Sif S
J Biol Chem; 2013 Dec; 288(49):35534-47. PubMed ID: 24189068
[TBL] [Abstract][Full Text] [Related]
14. DREAM interrupted: severing LIN-35-MuvB association in Caenorhabditis elegans impairs DREAM function but not its chromatin localization.
Goetsch PD; Strome S
Genetics; 2022 Jul; 221(3):. PubMed ID: 35554539
[TBL] [Abstract][Full Text] [Related]
15. Loss of the mammalian DREAM complex deregulates chondrocyte proliferation.
Forristal C; Henley SA; MacDonald JI; Bush JR; Ort C; Passos DT; Talluri S; Ishak CA; Thwaites MJ; Norley CJ; Litovchick L; DeCaprio JA; DiMattia G; Holdsworth DW; Beier F; Dick FA
Mol Cell Biol; 2014 Jun; 34(12):2221-34. PubMed ID: 24710275
[TBL] [Abstract][Full Text] [Related]
16. Structural mechanisms of DREAM complex assembly and regulation.
Guiley KZ; Liban TJ; Felthousen JG; Ramanan P; Litovchick L; Rubin SM
Genes Dev; 2015 May; 29(9):961-74. PubMed ID: 25917549
[TBL] [Abstract][Full Text] [Related]
17. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma.
Mack PC; Gandara DR; Bowen C; Edelman MJ; Paglieroni T; Schnier JB; Gelmann EP; Gumerlock PH
Clin Cancer Res; 1999 Sep; 5(9):2596-604. PubMed ID: 10499638
[TBL] [Abstract][Full Text] [Related]
18. A systematic approach identifies p53-DREAM pathway target genes associated with blood or brain abnormalities.
Rakotopare J; Lejour V; Duval C; Eldawra E; Escoffier H; Toledo F
Dis Model Mech; 2023 Oct; 16(10):. PubMed ID: 37661832
[TBL] [Abstract][Full Text] [Related]
19. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
[TBL] [Abstract][Full Text] [Related]
20. A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment.
Siebring-van Olst E; Blijlevens M; de Menezes RX; van der Meulen-Muileman IH; Smit EF; van Beusechem VW
Mol Oncol; 2017 May; 11(5):534-551. PubMed ID: 28296343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
